Browsing Other ICR Research by author "Parker, Chris"
Now showing items 1-20 of 37
-
A Four-Group Urine Risk Classifier for Predicting Outcome in Prostate Cancer Patients.
Connell, SP; Hanna, M; McCarthy, F; Hurst, R; Webb, M; et al. (2019-05-20)Objectives To develop a risk classifier using urine-derived extracellular vesicle RNA (UEV-RNA) capable of providing diagnostic information of disease status prior to biopsy, and prognostic information for men on active ... -
A Tool for Shared Decision Making on Referral for Prostate Biopsy in the Primary Care Setting: Integrating Risks of Cancer with Life Expectancy.
Verbeek, JFM; Nieboer, D; Parker, C; Kattan, MW; Steyerberg, EW; et al. (2019-04-22)Prostate cancer (PCa) testing involves a complex individually based decision making process. It should consider competing risks from other comorbidities when estimating a survival benefit from the early detection of ... -
Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data.
Vale, CL; Fisher, D; Kneebone, A; Parker, C; Pearse, M; et al. (2020-09-28)BACKGROUND:It is unclear whether adjuvant or early salvage radiotherapy following radical prostatectomy is more appropriate for men who present with localised or locally advanced prostate cancer. We aimed to prospectively ... -
Advances in targeted alpha therapy for prostate cancer.
De Vincentis, G; Gerritsen, W; Gschwend, JE; Hacker, M; Lewington, V; et al. (2019-11)Amongst therapeutic radiopharmaceuticals, targeted alpha therapy (TαT) can deliver potent and local radiation selectively to cancer cells as well as the tumor microenvironment and thereby control cancer while minimizing ... -
Advances in targeted alpha therapy for prostate cancer.
De Vincentis, G; Gerritsen, W; Gschwend, JE; Hacker, M; Lewington, V; et al.Amongst therapeutic radiopharmaceuticals, targeted alpha therapy (TαT) can deliver potent and local radiation selectively to cancer cells as well as the tumor microenvironment and thereby control cancer while minimizing ... -
An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223.
Sartor, O; Coleman, RE; Nilsson, S; Heinrich, D; Helle, SI; et al. (2017-05)Background Baseline clinical variables are prognostic for overall survival (OS) in patients with castration-resistant prostate cancer (CRPC). Their prognostic and predictive value with agents targeting bone metastases, ... -
appendix 8: Prostate cancer: eUpdate published online September 2016 (https://www.esmo.org/Guidelines/Genitourinary-Cancers).
Parker, C; Gillessen, S; Horwich, A; ESMO Guidelines Committee (2016-09) -
Best practice in active surveillance for men with prostate cancer: a Prostate Cancer UK consensus statement.
Merriel, SWD; Hetherington, L; Seggie, A; Castle, JT; Cross, W; et al. (2019-07)OBJECTIVES:To develop a consensus statement on current best practice of active surveillance (AS) in the UK, informed by patients and clinical experts. SUBJECTS AND METHODS:A consensus statement was drafted on the basis of ... -
Comparison of Transrectal Ultrasound Biopsy to Transperineal Template Mapping Biopsies Stratified by Multiparametric Magnetic Resonance Imaging Score in the PROMIS Trial.
Lovegrove, CE; Miah, S; El-Shater Bosaily, A; Bott, S; Brown, L; et al. (2020-01)Purpose We evaluated the performance of transrectal ultrasound guided systematic and transperineal template mapping biopsies with a 5 mm sampling frame stratified by the multiparametric magnetic resonance imaging Likert ... -
Current approaches to incorporation of radium-223 in clinical practice.
Parker, C; Heidenreich, A; Nilsson, S; Shore, N (2018-04)BACKGROUND:Treatment options for metastatic castration-resistant prostate cancer (mCRPC) have expanded in recent years and include cytotoxic agents (e.g., docetaxel and cabazitaxel), immunotherapy (e.g., sipuleucel-T), ... -
Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.
Ahmed, HU; El-Shater Bosaily, A; Brown, LC; Gabe, R; Kaplan, R; et al. (2017-02)Background Men with high serum prostate specific antigen usually undergo transrectal ultrasound-guided prostate biopsy (TRUS-biopsy). TRUS-biopsy can cause side-effects including bleeding, pain, and infection. Multi-parametric ... -
Diagnostic accuracy of the PROMIS study - Authors' reply.
Ahmed, HU; Brown, LC; Kaplan, R; Parker, C; Emberton, M (2017-07) -
Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial.
Parker, C; Zhan, L; Cislo, P; Reuning-Scherer, J; Vogelzang, NJ; et al. (2017-01)Symptomatic skeletal events (SSEs) commonly occur in patients with bone metastases, often leading to hospitalisations and decreased quality-of-life. In the ALSYMPCA trial, radium-223 significantly improved overall survival ... -
Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial.
Parker, C; Finkelstein, SE; Michalski, JM; O'Sullivan, JM; Bruland, Ø; et al. (2016-11)Background The phase 3 ALSYMPCA trial enrolled metastatic castration-resistant prostate cancer patients with or without baseline opioid use.Objective To assess the efficacy and safety of radium-223 dichloride (radium-223) ... -
False Positive Multiparametric Magnetic Resonance Imaging Phenotypes in the Biopsy-naïve Prostate: Are They Distinct from Significant Cancer-associated Lesions? Lessons from PROMIS.
Stavrinides, V; Syer, T; Hu, Y; Giganti, F; Freeman, A; et al.Background False positive multiparametric magnetic resonance imaging (mpMRI) phenotypes prompt unnecessary biopsies. The Prostate MRI Imaging Study (PROMIS) provides a unique opportunity to explore such phenotypes in ... -
Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial.
Vogelzang, NJ; Coleman, RE; Michalski, JM; Nilsson, S; O'Sullivan, JM; et al. (2017-02)Background Myelosuppression is common in patients with progressive castration-resistant prostate cancer and bone metastases. Radium-223 prolongs overall survival in these patients but may cause myelosuppression; understanding ... -
Low-risk Prostate Cancer: Identification, Management, and Outcomes.
Moschini, M; Carroll, PR; Eggener, SE; Epstein, JI; Graefen, M; et al. (2017-08)Context The incidence of low-risk prostate cancer (PCa) has increased as a consequence of prostate-specific antigen testing.Objective In this collaborative review article, we examine recent literature regarding low-risk ... -
Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study.
Brown, LC; Ahmed, HU; Faria, R; El-Shater Bosaily, A; Gabe, R; et al. (2018-07)Background Men with suspected prostate cancer usually undergo transrectal ultrasound (TRUS)-guided prostate biopsy. TRUS-guided biopsy can cause side effects and has relatively poor diagnostic accuracy. Multiparametric ... -
No association between polygenic risk scores for cancer and development of radiotherapy toxicity.
Barnett, GC; Kerns, SL; Dorling, L; Fachal, L; Aguado-Barrera, ME; et al. (Elsevier BV, 2022-07-12)PURPOSE: To test whether updated polygenic risk scores (PRS) for susceptibility to cancer affect risk of radiotherapy toxicity. EXPERIMENTAL DESIGN: Analyses included 9,717 patients with breast (n=3,078), prostate (n=5,748) ... -
Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer.
Kishan, AU; Tendulkar, RD; Tran, PT; Parker, CC; Nguyen, PL; et al. (2018-05-15)Context Currently, salvage radiotherapy (SRT) is the only known curative intervention for men with recurrent disease following prostatectomy. Critical issues in the optimal selection and management of men being considered ...